Developing category-defining, first-in-class therapies for patients with kidney disease, R1 Therapeutics has secured an $80.5M Series A investment from Samsara BioCapital. The San Francisco Bay Area-based company is advancing its lead asset, AP306, a pan phosphate active transport inhibitor designed to treat hyperphosphatemia in patients with chronic kidney disease (CKD). AP306, which has demonstrated significant reduction in serum phosphate levels in a Phase 2a study, is distinguished as the only agent that blocks the โactiveโ transport of phosphate for CKD treatment. R1 plans to initiate a Phase 2b study in 2026.
R1 Therapeutics Raises $80.5M
Get the full R1 Therapeutics company profile
Access contacts, investors, buying signals & more
From the source
bioSeedin ยท Sep 30, 2026๐ฐ ๐๐๐๐ค๐ฅ๐ฒ ๐๐ข๐จ๐ฉ๐ก๐๐ซ๐ฆ๐ ๐๐๐ฃ๐จ๐ซ ๐ ๐ข๐ง๐๐ง๐๐ข๐ง๐ ๐๐จ๐ฎ๐ง๐๐ฎ๐ฉ This week's major biotech financing announcements highlighted continued investment in clinical-stage programs, radiopharmaceutical infrastructure, next-generation cell therapies and novel immunology approaches.
๐. NorthStar Medical Radioisotopes โ ๐๐ฉ ๐ญ๐จ $๐๐๐๐ ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐ ๐ข๐ง๐๐ง๐๐ข๐ง๐ NorthStar secured a growth financing commitment of up to $185 million led by Hercules Capital. The funding will support expansion of actinium-225 production and radiopharmaceutical manufacturing capacity, strengthening infrastructure for targeted radioligand therapies. ๐. Sagimet Biosciences โ $๐๐๐๐ ๐๏ฟฝ
Other recently funded companies
View all
SedMed
SedMed is a Connecticut-based company focused on making one of the most under-supported and high-risk parts of daily life safer and easier: getting on and off the toilet. We design the SedMed Toilet Lift, a mechanical toilet-mounted lift that helps provide a more controlled way down and added support back up for people who need extra sit-to-stand assistance during toileting. The SedMed Toilet Lift mounts directly to the toilet like a toilet seat and does not require electricity, motors, wiring, or a plug. It is low maintenance, easy to clean, and built to help reduce hard landings while giving added help with standing. Learn more and shop at sed-med.com
$4.0M Unknown
today
Zeal
Merchant churn. Net new MIDs. Differentiation. Three things we hear in almost every conversation with PSPs, acquirers, and ISOs. If they resonate, you're in the right place. Zeal turns payment terminals into a platform. We don't process payments. We connect loyalty, analytics, merchant engagement, and third-party services to your existing fleet through a single SDK. No new hardware. No integration headaches. Day-one value for every merchant on your books. Less churn. Merchants stay when the terminal delivers value beyond payments. More MIDs. A differentiated offering means more merchants choose you. New revenue. Third parties integrate with Zeal to reach your fleet, turning terminals from infrastructure into a distribution channel. For retailers: the customer intelligence that powers e-commerce, at your physical point of sale. Underneath it all, we're building the data infrastructure for offline payment transactions. Every tap, every basket, every visit, structured and actionable for the first time. Partner-obsessed. Built in London. Backed by Raed Ventures, Pinnacle Capital, and Cur8 Capital.
Biggest recent Biotechnology rounds
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 |  NeuroEM Therapeutics United States | Unknown |
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  doxx.net United States | Series a | $38.0M | today |
| 2 |  Novele United States | Series a | $17.0M | today |
| 3 |
.png&w=3840&q=75)
